Plasma-Derived Extracellular Vesicles Inhibit Lipopolysaccharide-Induced Apoptosis and Oxidative Stress in Human AC16 Cardiomyocytes

Yuli Yang, T. J. Yang, 裕二 池谷, Youshuang ZhuCurrent 2026 · DOI

TL;DR

This study reveals that extracellular vesicles (EVs) derived from human plasma can protect cardiomyocytes from sepsis-induced damage. EVs effectively reduce apoptosis and oxidative stress in heart cells exposed to lipopolysaccharide (LPS), a key bacterial component, by inhibiting the NF-κB signaling pathway. These findings highlight EVs as promising therapeutic candidates for sepsis-associated cardiovascular dysfunction.

What Problem Does This Paper Address?

Sepsis, a life-threatening condition, often leads to myocardial dysfunction, significantly increasing mortality. A major contributor to this cardiac damage is lipopolysaccharide (LPS), a component of Gram-negative bacteria, which triggers excessive oxidative stress and apoptosis in cardiomyocytes. While extracellular vesicles (EVs) are known for their cardioprotective roles, their specific impact on LPS-induced cardiomyocyte injury, particularly concerning the underlying molecular mechanisms, remained unclear. This paper aims to elucidate whether plasma-derived EVs can mitigate LPS-induced apoptosis and oxidative stress in human cardiomyocytes and to explore the signaling pathways involved.

Methods

The researchers utilized a combination of in vitro techniques to investigate the effects of plasma-derived EVs on human AC16 cardiomyocytes challenged with LPS.

  • EV Isolation and Characterization: Plasma samples from healthy donors were processed to isolate EVs using size exclusion chromatography (SEC). The isolated EVs were then characterized for their size distribution (nanoparticle tracking analysis - NTA), morphology (transmission electron microscopy - TEM), and the presence of specific EV markers (CD63, CD9, Tsg101) via Western blotting.
  • Cell Culture and Treatment: AC16 cardiomyocytes were cultured and then treated with LPS alone, or pre-treated with plasma-derived EVs before LPS exposure. In some experiments, an NF-κB agonist (Betulinic acid) was used to investigate the role of this signaling pathway.
  • Apoptosis Assessment: Cellular apoptosis was measured using flow cytometry with Annexin V-FITC and propidium iodide (PI) staining. Western blotting was employed to analyze the expression levels of key apoptosis-related proteins, including Bax, Bcl-2, and cleaved Caspase-3.
  • Oxidative Stress Measurement: Intracellular reactive oxygen species (ROS) levels were quantified using a ROS assay kit and flow cytometry.
  • NF-κB Signaling Analysis: Western blotting was used to assess the phosphorylation and total protein levels of NF-κB p65 and IκBα. The subcellular localization of NF-κB p65 (cytoplasmic vs. nuclear) was also investigated using a nuclear and cytoplasmic protein extraction kit followed by Western blotting.
  • Pharmacological Rescue Experiment: To confirm the role of NF-κB signaling, AC16 cells were treated with EVs and an NF-κB agonist in the presence of LPS, and then apoptosis and ROS levels were re-evaluated.
  • Statistical Analysis: Data were analyzed using independent sample t-tests and two-way ANOVA, with a p-value less than 0.05 considered statistically significant.

Datasets

Not discussed in the paper. The study utilized commercially available cell lines and reagents.

Key Insights and Ideas

  • EVs as a Protective Shield: The most striking finding is that plasma-derived EVs can significantly protect cardiomyocytes from LPS-induced damage. This suggests that EVs carry inherent protective factors that can counteract the detrimental effects of sepsis.
  • Dual Action: Anti-Apoptosis and Antioxidant: EVs don't just tackle one problem; they address both the programmed cell death (apoptosis) and the damaging accumulation of reactive oxygen species (ROS) triggered by LPS. This dual action is crucial for preserving cardiac function.
  • NF-κB Signaling as the Key Mediator: The study strongly implicates the NF-κB signaling pathway as the central mechanism through which EVs exert their protective effects. Specifically, EVs appear to inhibit the activation and nuclear translocation of NF-κB p65, a critical transcription factor involved in inflammation and apoptosis.
  • Targeted Intervention: The use of an NF-κB agonist in a rescue experiment provided compelling evidence. When NF-κB was artificially activated, the protective benefits of EVs were diminished, reinforcing the idea that EVs work by modulating this specific pathway.
  • Potential for Novel Therapeutics: The findings open up exciting possibilities for developing EV-based therapies for sepsis-induced heart problems, offering a more targeted and potentially less toxic approach compared to traditional treatments.

Key Results

  • LPS Induces Damage: LPS treatment significantly increased apoptosis (measured by Annexin V/PI staining and Bax/Bcl-2 ratios) and ROS levels in AC16 cardiomyocytes.
  • EVs Mitigate Damage: Pre-treatment with plasma-derived EVs markedly reduced LPS-induced apoptosis and ROS accumulation in AC16 cells.
  • NF-κB Inhibition: LPS treatment led to increased phosphorylation of NF-κB p65 and IκBα, and promoted the nuclear translocation of p65. EVs treatment reversed these effects, reducing p65 phosphorylation and promoting its retention in the cytoplasm.
  • NF-κB Agonist Reverses EV Effects: When an NF-κB agonist was administered alongside EVs and LPS, the protective effects of EVs on apoptosis and ROS levels were partially abolished, confirming the role of NF-κB signaling.

Limitations and Future Work

The authors acknowledge several limitations:

  • In Vitro Model: The study was conducted using an in vitro AC16 cell model, which may not fully capture the complexity of in vivo sepsis or cardiac tissue.
  • Causal Role of NF-κB: While strong associative evidence is presented, the direct causal role of NF-κB inhibition in mediating EV protection was not definitively proven. The use of a pharmacological rescue agent (Betulinic acid) is noted as having potential off-target effects.
  • EV Cargo Heterogeneity: The specific molecular components (e.g., miRNAs, proteins, lipids) within the EVs responsible for the observed effects remain unidentified.

Future work suggested includes:

  • In Vivo Studies: Validating these findings in animal models of sepsis-associated myocardial injury.
  • Mechanistic Studies: Employing more specific NF-κB inhibitors and conducting NF-κB loss- or gain-of-function assays for stronger mechanistic evidence.
  • EV Cargo Profiling: Identifying the active EV components through techniques like miRNA sequencing and functional validation of candidate molecules.
  • Exploring Other Pathways: Investigating the potential involvement of other signaling pathways beyond NF-κB.

Summary updated

Abstract

Sepsis is frequently accompanied by myocardial dysfunction, which significantly worsens clinical outcomes. Lipopolysaccharide (LPS), a key component of Gram-negative bacteria, induces excessive oxidative stress and apoptosis in cardiomyocytes, contributing to sepsis-associated cardiac injury. Plasma-derived extracellular vesicles (EVs) have emerged as important mediators of intercellular communication and cardiovascular protection; however, their role in LPS-induced cardiomyocyte injury remains unclear. In this study, human AC16 cardiomyocytes were exposed to LPS in the presence or absence of plasma-derived EVs. Intracellular reactive oxygen species (ROS) production and apoptosis were assessed by flow cytometry, while apoptosis-related proteins and NF-κB signaling components were analyzed by Western blotting. The involvement of NF-κB signaling was further examined using pharmacological rescue experiments. Our results demonstrate that EV treatment markedly attenuated LPS-induced ROS accumulation and cardiomyocyte apoptosis. These protective effects were associated with reduced phosphorylation of NF-κB p65 and IκBα, as well as inhibition of p65 nuclear translocation. Notably, activation of NF-κB signaling abolished the anti-apoptotic and antioxidative effects of EVs under LPS challenge. Collectively, these findings suggest that plasma-derived EVs mitigate LPS-induced oxidative stress and apoptosis in human cardiomyocytes, potentially through modulation of NF-κB signaling. This study provides molecular insights into the cardioprotective actions of EVs and supports their potential as therapeutic candidates for sepsis-associated cardiovascular dysfunction.
BibTeX
@inproceedings{yang2026plasma,
  author = {Yuli Yang and T. J. Yang and 裕二 池谷 and Youshuang Zhu},
  title = {{Plasma-Derived Extracellular Vesicles Inhibit Lipopolysaccharide-Induced Apoptosis and Oxidative Stress in Human AC16 Cardiomyocytes}},
  booktitle = {Current},
  year = {2026},
  doi = {10.3390/cimb48020174},
}
Figure